A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500823-61-00

Acronym

CA099-003

Enrollment

Registered

2023-05-24

Start date

2024-04-08

Completion date

2025-07-24

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumours

Brief summary

Incidence of DLTs, AEs, SAEs, AEs leading to discontinuation, and deaths.

Detailed description

Summary measures of BMS-986408 PK parameters in plasma, such as, but not limited to, Cmax, Tmax, and AUC (0-T), from concentration-time data during BMS-986408 monotherapy and in combination with nivolumab or nivolumab and ipilimumab., ORR and DOR per RECIST v1.1.

Interventions

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

DRUGIpilimumab

DRUGDGKα/ζ Inhibitor

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
Summary measures of BMS-986408 PK parameters in plasma, such as, but not limited to, Cmax, Tmax, and AUC (0-T), from concentration-time data during BMS-986408 monotherapy and in combination with nivolumab or nivolumab and ipilimumab., ORR and DOR per RECIST v1.1.	—

Primary

Measure	Time frame
Incidence of DLTs, AEs, SAEs, AEs leading to discontinuation, and deaths.	—

Countries

France, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026